JP2022540611A5 - - Google Patents
Info
- Publication number
- JP2022540611A5 JP2022540611A5 JP2022501134A JP2022501134A JP2022540611A5 JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061352A JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| US62/872,915 | 2019-07-11 | ||
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Division JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540611A JP2022540611A (ja) | 2022-09-16 |
| JP2022540611A5 true JP2022540611A5 (https=) | 2023-07-12 |
| JP7661299B2 JP7661299B2 (ja) | 2025-04-14 |
Family
ID=74115317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501134A Active JP7661299B2 (ja) | 2019-07-11 | 2020-07-08 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (https=) |
| EP (1) | EP3997127A4 (https=) |
| JP (2) | JP7661299B2 (https=) |
| KR (1) | KR20220034167A (https=) |
| CN (3) | CN119080930A (https=) |
| AU (1) | AU2020310894A1 (https=) |
| BR (1) | BR112022000216A2 (https=) |
| CA (1) | CA3146566A1 (https=) |
| CO (1) | CO2022001195A2 (https=) |
| IL (1) | IL289585A (https=) |
| MX (1) | MX2022000325A (https=) |
| PH (1) | PH12022550056A1 (https=) |
| WO (1) | WO2021007371A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (https=) * | 2014-05-30 | 2018-04-14 | ||
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| CA3204628A1 (en) * | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MX2023008285A (es) * | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo anti-dll3-farmaco. |
| MX2023012614A (es) * | 2021-05-08 | 2023-11-03 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Molecula de union contra dll3 y uso de la misma. |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| JP2024534892A (ja) * | 2021-09-02 | 2024-09-26 | メモリアル スローン ケタリング キャンサー センター | 抗ｄｌｌ３抗体及びその使用 |
| CA3240378A1 (en) * | 2021-12-23 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody |
| EP4482859A1 (en) | 2022-02-27 | 2025-01-01 | Boehringer Ingelheim International GmbH | Bispecific antibodies against cd277 and a tumor-antigen |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| AU2007325872B2 (en) * | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| NZ626242A (en) * | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
-
2020
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022540611A5 (https=) | ||
| JP7235256B2 (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| CN105579471B (zh) | 结合人程序性死亡配体1(pd-l1)的抗体 | |
| JP2009100745A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP7624497B2 (ja) | ヒトｐｄ－ｌ２抗体およびその使用方法 | |
| JP2005518789A5 (https=) | ||
| JP7713995B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| US12325747B2 (en) | Human PD-L1 antibodies and methods of use therefor | |
| JP2024506315A5 (https=) | ||
| JP2022538117A5 (https=) | ||
| US20250129167A1 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| JP2024540148A5 (https=) | ||
| CN112979795A (zh) | 抗体组合产品及其在新冠肺炎检测中应用 | |
| RU2021139258A (ru) | Dll3-нацеливающие антитела и их применения | |
| CN118240079A (zh) | 抗脂联素抗体、检测脂联素的试剂和试剂盒 | |
| CN120424221B (zh) | 靶向德曲妥珠单抗的抗体及其用途 | |
| TW201915016A (zh) | 單株抗體或其抗原結合片段及其用途 | |
| JP2025512888A (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体ならびにその使用方法 | |
| CN120500500A (zh) | 一种抗gpr87的抗体及其制备方法和应用 | |
| CN121975014A (en) | Anti-DLL 3 antibodies and related products and uses thereof | |
| KR20250064725A (ko) | 사스 코로나바이러스 2 중화를 위한 이뮤노글로불린 a 항체 및 이의 용도 | |
| JP2024531913A5 (https=) |